Liminal BioSciences Inc. PFSCF

Plasminogen Wound Healing

[jakethesnake2]

I noticed that in the National Bank Financial report issued yesterday the analyst has estimated that commercialization for Wound Healing will be in 2022 but CIBC"s most recent report from last month estimated in H2 2018. That's quite a difference in timeline so I asked Fred for his input.
Read his reply below:



Good morning Jack,
 
As a company, we normally only double-check for factual inaccuracies in any analyst draft reports before they go ahead and launch coverage. We will provide comments but ultimately, it is the analyst’s decision to use whatever number or timeline he wants in his report.
 
In the specific case of wound healing, we expect to file a CTA (clinical trial application) with the Swedish regulatory authorities, have it cleared and initiate the clinical program in the second half of 2016. We have not had the discussion with them yet and therefore it is difficult for me right now to give you a good idea of what the program will look like and how long it is going to take. Once all of that is done, I will have a much better idea of what kind of timelines we are looking at  precisely.
 
However, I highly doubt it will that long before we get to market with that. If all goes well and the product is as efficacious as we think it will, we’ll reach market approval way before 2022. Again, I cannot provide more precision at the moment as I don’t even have an idea of what is and will be required in the upcoming phase 2.
 
More to come over the next few months
 
Thx
 
Best regards
 
Fred
 

Frdric Dumais, B. Comm., LLB.
 
Directeur principal, Communications et relations avec les investisseurs
Senior Director, Communications and Investor Relations
 
ProMetic Sciences de la Vie inc.
ProMetic Life Sciences Inc.
 
440 boul. Armand-Frappier, bureau (suite) 300
Laval, Qubec, Canada
H7V 4B4
Tel. : [phone]
Fax : [phone]
Mobile : [phone]
[e-mail]
www.prometic.com